Results 11 to 20 of about 25,067 (205)

Overexpressed ABCB1 Induces Olaparib-Taxane Cross-Resistance in Advanced Prostate Cancer [PDF]

Translational Oncology, 2019
Castration-resistant prostate cancer remains as an incurable disease. Exploiting DNA damage repair defects via inhibition of poly (ADP-ribose) polymerase (PARP) is becoming an attractive therapeutic option.
Alan P Lombard, Chengfei Liu, Cameron M Armstrong, Leandro S D'Abronzo, Wei Lou, Hongwu Chen, Marc Dall'Era, Paramita M Ghosh, Christopher P Evans, Allen C Gao   +9 more
doaj   +2 more sources

IGFBP3 promotes resistance to Olaparib via modulating EGFR signaling in advanced prostate cancer [PDF]

iScience
Summary: Olaparib is a pioneering PARP inhibitor (PARPi) approved for treating castration-resistant prostate cancer (CRPC) tumors harboring DNA repair defects, but clinical resistance has been documented.
Amy R. Leslie, Shu Ning, Cameron M. Armstrong, Leandro S. D’Abronzo, Masuda Sharifi, Zachary A. Schaaf, Wei Lou, Chengfei Liu, Christopher P. Evans, Alan P. Lombard, Allen C. Gao   +10 more
doaj   +2 more sources

Efficacy and safety of olaparib in advanced ovarian cancer: a meta-analysis

Journal of Obstetrics and Gynaecology, 2023
This study aimed to evaluate the efficacy and safety of olaparib for the treatment of advanced ovarian cancer. All studies that assessed the efficacy and safety of olaparib in advanced ovarian cancer were searched in PubMed, Embase, and Web of Science ...
Yuanyuan Yang, Xiaoyun Yang, Huaifang Li, Xiaowen Tong, Xinxian Zhu   +4 more
doaj   +2 more sources

The combination of olaparib and camptothecin for effective radiosensitization [PDF]

Radiation Oncology, 2012
Background Poly (ADP-ribose) polymerase-1 (PARP-1) is a key enzyme involved in the repair of radiation-induced single-strand DNA breaks. PARP inhibitors such as olaparib (KU-0059436, AZD-2281) enhance tumor sensitivity to radiation and to topoisomerase I
Miura Katsutoshi, Sakata Koh-ichi, Someya Masanori, Matsumoto Yoshihisa, Matsumoto Hideki, Takahashi Akihisa, Hareyama Masato   +6 more
doaj   +2 more sources

A Quaternary Solid Dispersion System for Improving the Solubility of Olaparib

Solids
To improve the low solubility of poorly water soluble olaparib, in the following study, we prepared olaparib-loaded quaternary solid dispersions with hypromellose, Tween 20 or Labrasol, and colloidal silica.
Tae-Han Yun, Jeong-Gyun Lee, Kyu-Ho Bang, Jung-Hyun Cho, Kyeong-Soo Kim   +4 more
doaj   +2 more sources

The efficacy and safety of olaparib in the treatment of cancers: a meta-analysis of randomized controlled trials

Cancer Management and Research, 2018
Xiao Xia Guo,1,* Hong Li Wu,2,* Hong Yun Shi,3 Lei Su,3 Xi Zhang3 1Department of Obstetrics and Gynecology, Sichuan Academy of Medical Sciences, Sichuan Provincial People’s Hospital, Chengdu, 2Department of Obstetrics and Gynecology, Hebei ...
Guo XX, Wu HL, Shi HY, Su L, Zhang X
doaj   +1 more source

Olaparib monotherapy or combination therapy in lung cancer: an updated systematic review and meta- analysis [PDF]

Frontiers in Oncology
Background and aimsImpaired double strand DNA repair by homologous repair deficiency (HRD) leads to sensitivity to poly ADP ribose polymerase (PARP) inhibition.
Sajjad Hajihosseini, Ehsan Emami, Seyed Amirali Zakavi, Parnia Jochin, Mehregan Shahrokhi, Sahar Khoshravesh, Mitra Goli, Mohaddeseh Belbasi, Gisou Erabi, Niloofar Deravi   +9 more
doaj   +2 more sources

Clinical Impact of Olaparib for Platinum-Sensitive Recurrent Ovarian Cancer

Diseases
Background/Objectives: Olaparib, a poly ADP ribose polymerase inhibitor, has been effective in prolonging progression-free survival in platinum-sensitive recurrent ovarian cancer.
Hiroaki Ishida, Megumi Manrai, Akiko Takashima, Hiroki Egashira, Mizuki Nonaka, Hideaki Shimada   +5 more
doaj   +2 more sources

Patient-reported outcomes in castration-resistant prostate cancer with bone metastases treated with radium-223 with or without olaparib. [PDF]

Cancer
Abstract Background The combination of olaparib plus radium‐223 improved progression‐free survival in patients with metastatic castration‐resistant prostate cancer with bone metastases (BM) in the multicenter, randomized, phase 2 COMRADE trial (NCT03317391). Here, the patient‐reported outcome (PRO) analysis of this trial is reported.
McKay RR, Xie W, Ajmera A, Araneta A, Folefac E, Hussain A, Kyriakopoulos CE, Olson A, Parikh M, Parikh R, Saraiya B, Shapiro GI.   +11 more
europepmc   +2 more sources

Olaparib Induced Senescence is Bypassed through G2/M Checkpoint Override in Olaparib Resistant Prostate Cancer [PDF]

, 2022
PARP inhibition represents the dawn of precision medicine for treating prostate cancer. Despite this advance, questions remain regarding the use of PARP inhibitors (PARPi’s) for the treatment of this disease, including 1) how specifically do PARPi ...
Sharifi, Masuda, Lombard, Alan P, Chen, Xinbin, Chen, Hong-Wu, Gao, Allen C, Dall’Era, Marc, Leslie, Amy R, Evans, Christopher P, D'Abronzo, Leandro S, Armstrong, Cameron M, D’Abronzo, Leandro S, Ning, Shu, Lou, Wei, Dall'Era, Marc   +13 more
core   +1 more source